GKGoran Kungulovski

Goran Kungulovski

*This is an algorithmically generated author record based on publicly available information.

Goran Kungulovski has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mutations in Chromatin Regulator Genes Associate With TMB and Immunotherapy Response in Melanoma

    by Marija Gjorgjievska, Djansel Bukovec, Andzelka Ilieva, Milan Risteski, Ivan Kungulovski, Zan Mitrev, Aimilios Lallas, Goran Kungulovski

    Melanoma is a high‐tumor‐mutational‐burden (TMB) cancer, largely driven by ultraviolet‐induced DNA damage. Although TMB predicts response to immune checkpoint inhibitors (ICIs), the genomic factors underlying its variability remain unclear. In addition to canonical DNA‐repair defects such as mismatch repair (MMR) and POLE/POLD1 mutations, alterations in chromatin regulators (CRs) may influence genome stability and mutational load. We analyzed melanoma cohorts from the MSK‐ICI, TCGA, MSK‐Met, DFCI, and UCLA datasets. TMB was compared between CR‐mutant and CR–wild‐type tumors and overall cohorts, along with gene‐level analyses of individual CRs. Associations between the number of CR mutations and TMB were assessed. Overall survival (OS) in ICI‐treated patients was evaluated using Kaplan–Meier and Cox models, with TCGA as a non–ICI‐treated comparator. Across datasets, CR‐mutant melanomas consistently exhibited significantly higher TMB than CR–wild‐type tumors. Several CRs were linked to elevated TMB, comparable to MMR‐ or POLE/POLD1‐mutant tumors. Multiple CR alterations showed a positive linear relationship with TMB. In ICI‐treated cohorts, CR‐mutant tumors had significantly longer OS, while this link was not observed in non–ICI‐treated cases. These findings suggest that CR mutations define a subset of melanomas with high TMB and improved response to ICIs, warranting prospective validation as predictive biomarkers.

  • Open Access

    PRC2-binding regions are hotspots of DNA methylation entropy in pre-cancer and cancer

    by Djansel Bukovec, Monika Simjanoska Misheva, Marija Gjorgjievska, Goran Kungulovski

    DNA methylation aberrations and variability are pervasive features of cancer, yet their relationship with chromatin regulation remains incompletely understood. Across hundreds of matched tumor–normal methylomes, regions with the highest methylation entropy in both tumor and normal tissues were consistently enriched for PRC2-associated factors. In tumors, inter-sample methylation variability was increased across the full range of PRC2-associated levels, while mean methylation progressively increased from low- to high-PRC2-binding regions; this gradient was substantially weaker in matched normal tissues. PRC2-associated regions with higher DNA methylation levels were preferentially associated with poised and repressed chromatin states, reduced chromatin accessibility, and reduced gene expression. Independent normal–precancer–cancer cohorts showed that this PRC2-associated methylation state emerges early, with precancerous and malignant tissues displaying highly similar profiles that are distinct from those of healthy tissues. Single-cell colon cancer methylomes independently confirmed increased methylation entropy at PRC2 regions. Higher PRC2-region entropy was associated with scores reflecting hypoxic states, aggressive tumor features, and poorer survival outcomes. Collectively, these findings identify PRC2-binding regions as hotspots of DNA methylation variability that become dysregulated during tumorigenesis.

  • Open Access

    Cancer type-specific profiling of chromatin regulator mutations identifies recurrent and co-occurring gene sets associated with improved survival following immune checkpoint therapy

    by Djansel Bukovec, Marija Gjorgjievska, Sara Kocevska, Mia Nikolova, Lina Mirkovikj, Ivan Kungulovski, Zan Mitrev, Goran Kungulovski

    Mutations in chromatin regulator (CR) genes are frequent across human cancers and have been associated with increased tumor mutational burden (TMB) and improved response to immune checkpoint inhibitor (ICI) treatment. Here, using discovery and independent validation cohorts, we resolved these associations at the level of individual cancer types and investigated whether shared CR mutation patterns emerge across colorectal cancer, melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, bladder cancer, esophagogastric cancer, pancreatic adenocarcinoma, prostate cancer, and breast cancer. For each cancer type, we identified a distinct set of pro-survival CR genes, whose mutations were associated with improved survival following ICI treatment. We further identified a subset of recurrent CRs that were associated with improved ICI outcomes across many cancer types, although the magnitude of the association varied between cancers. Co-occurrence of mutations in two or more CRs was associated with further improvement in survival, while several individual CR genes showed particularly robust associations with favorable ICI outcomes. Across cancer types, CR-altered groups consistently displayed higher TMB than their corresponding CR-unaltered groups. Transcriptomics-based deconvolution further revealed cancer-type-specific differences in the tumor microenvironment associated with CR mutations. Together, these findings demonstrate both cancer-specific and recurrent patterns of CR mutations associated with improved outcomes following ICI treatment and further establish a relationship between CR alterations, increased TMB, and ICI response.

  • Open Access

    DNA methylation variability defines a fundamental dimension of tumor epigenomes linked to genomic instability, tumor aggressiveness, and clinical outcomes

    by Djansel Bukovec, Blagojche Gjorgjioski, Monika Simjanoska Misheva, Goran Kungulovski

    Background: Tumors exhibit substantial cellular and molecular diversity driven by genetic and epigenetic mechanisms. Large-scale profiling efforts have established aberrant DNA methylation as a universal hallmark of cancer. Beyond changes in mean methylation levels, tumor tissues exhibit elevated DNA methylation variability at specific genomic regions within and across tumors. This constitutes a fundamental dimension of cancer epigenomes, reflecting disrupted maintenance of epigenomic states and stochastic drift, which may enable adaptation to the microenvironment, phenotypic plasticity, invasion, disease progression, and treatment resistance. However, the genome-wide organization and functional consequences of DNA methylation variability across cancer types remain incompletely understood. Methods: We analyzed paired tumor–normal DNA methylation profiles across 16 cancer types to systematically quantify DNA methylation variability. Pan-cancer DNA methylation variability was consistently observed using complementary statistical approaches and multiple modes of data representation. We identified cancer-specific and pan-cancer differentially variable regions and evaluated their associations with genomic features, transcriptional and chromatin regulators, and biological processes. Variability was quantified using three measures per sample: the proportion of intermediately methylated sites (PIM), genome-wide Shannon entropy, and a DNA methylation–based stemness index. Associations with genomic instability, tumor biological features, and clinical outcomes were subsequently assessed. Results: Tumor samples consistently exhibited higher DNA methylation variability than matched normal tissues, reflected by increased dispersion and wider interquartile ranges. Pan-cancer variably methylated regions were depleted in promoters and enriched in open sea regions, in heterochromatic H3K27me3-decorated PRC2-repressed domains, and at enhancers. They preferentially contained motifs for transcription factors involved in developmental regulation. Elevated DNA methylation variability, captured by higher PIM, entropy, and stemness scores, was associated with increased genomic instability manifested by higher aneuploidy, increased DNA break points, a greater fraction of the genome altered, and increased tumor mutational burden, as well as with aggressive tumor features such as lymph node involvement, post-therapy neoplasm events, and elevated hypoxia scores. Importantly, tumors with high DNA methylation variability exhibited significantly worse overall, progression-free, and disease-free survival. Conclusions: DNA methylation variability is a pervasive and clinically relevant feature of tumor epigenomes, reflecting epigenetic and genetic instability, expanded regulatory plasticity, and tumor aggressiveness.

  • Open Access

    Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy

    by Marija Gjorgjievska, Djansel Bukovec, Sanja Mehandziska, Milan Risteski, Ivan Kungulovski, Zan Mitrev, Goran Kungulovski

    In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators


  • Open Access

    Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy

    by Marija Gjorgjievska, Sanja Mehandziska, Djansel Bukovec, Milan Risteski, Ivan Kungulovski, Zan Mitrev, Goran Kungulovski

    In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators (CRs). We analyzed the distribution and characteristics of well-studied CRs across tens of thousands of tumor samples. Our analysis revealed that tumors with mutations in CRs are associated with high tumor mutational burden (TMB). The co-occurrence of mutations in multiple CRs was linked with a further increase in TMB. Given that TMB may predict the clinical response to immune checkpoint inhibitor (ICI) treatment, we investigated the relationship between mutations in CRs and ICI response. We found that patients harboring mutations in CRs exhibited improved responses to ICI treatment, comparable to those with deficiencies in canonical DNA repair pathways. Overall, this study uncovered significant relationships between mutations in chromatin regulators and critical features of cancer, underscoring the need for further functional and clinical studies.

  • Open Access

    Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy

    by Goran Kungulovski, Marija Gjorgjievska, Sanja Mehandziska, Djansel Bukovec, Milan Risteski, Ivan Kungulovski, Zan Mitrev

    In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators (CRs). We analyzed the distribution and characteristics of well-studied CRs across tens of thousands of tumor samples. Our analysis revealed that tumors with mutations in CRs are associated with high tumor mutational burden (TMB). The co-occurrence of mutations in multiple CRs was linked with a further increase in TMB. Given that TMB may predict the clinical response to immune checkpoint inhibitor (ICI) treatment, we investigated the relationship between mutations in CRs and ICI response. We found that patients harboring mutations in CRs exhibited improved responses to ICI treatment, comparable to those with deficiencies in canonical DNA repair pathways. Overall, this study uncovered significant relationships between mutations in chromatin regulators and critical features of cancer, underscoring the need for further functional and clinical studies.


  • Rhizosphere microbiomes of resurrection plants Ramonda serbica and R. nathaliae: comparative analysis and search for bacteria mitigating drought stress in wheat (Triticum aestivum L.)

    by Jelena Lozo, Nemanja Ristović, Goran Kungulovski, Živko Jovanović, Tamara Rakić, Slaviša Stanković, Svetlana Radović

    Rhizosphere microbial communities play an important role in maintaining the health and productivity of the plant host. The rhizobacteria Pseudomonas putida P2 of Ramonda serbica and Bacillus cereus P5 of R. nathaliae were selected for treatment of the Belija wheat cultivar because of their plant growth-promoting (PGP) properties. Compared to the non-treated drought-stressed plants, the plants treated with rhizobacteria showed increased activity of the two major antioxidant enzymes, superoxide dismutase, and ascorbate peroxidase. Plants treated with the B. cereus P5 strain exhibited higher proline content under drought stress, suggesting that proline accumulation depends on the relative water content (RWC) status of the plants studied. Inoculation of wheat seeds with the P. putida P2 strain improved water status by increasing RWC and alleviating oxidative stress by reducing H2O2 and malondialdehyde concentrations in plants exposed to severe drought, possibly also helping plants to overcome drought through its 1-aminocyclopropane-1-carboxylic acid deaminase activity. Analysis of data from Next Generation sequencing (NGS) revealed that the dominant bacterial taxa in the rhizosphere of resurrection plants R. serbica and R. nathaliae were extremophilic, thermotolerant, Vicinamibacter silvestris, Chthoniobacter flavus, and Gaiella occulta. From the fungi detected Penicillium was the most abundant in both samples, while Fusarium and Mucor were present only in the rhizosphere of R. serbica and the entomopathogenic fungi Metarhizium, and Tolypocladiumu only in the rhizosphere of R. nathaliae. The fungal communities varied among plants, suggesting a stronger environmental influence than plant species. Our study demonstrates the importance of in vivo experiments to confirm the properties of PGP bacteria and indicates that the rhizosphere of resurrection plants is a valuable source of unique microorganisms that can be used to improve the drought stress tolerance of crops.


  • Open Access

    Case Report: Omicron BA.2 Subvariant of SARS-CoV-2 Outcompetes BA.1 in Two Co-infection Cases

    by Marija Gjorgjievska, Sanja Mehandziska, Aleksandra Stajkovska, Slavica Pecioska-Dokuzovska, Anica Dimovska, Idriz Durmish, Sara Ismail, Teodora Pavlovska, Antonija Stojchevska, Haris Amedi, et al.

    Trends from around the world suggest that the omicron BA.2 subvariant is increasing in proportion to the original BA.1 subvariant. Here we report two cases of co-infection with omicron BA.1 and omicron BA.2 in co-exposed individuals. In both individuals, genome sequencing and/or S-gene specific PCR identified omicron BA.1 at early time-points, which was replaced by omicron BA.2 at later time-points of the infection. The timeline of our data supports the proposition that BA.2 outcompetes BA.1 in a real-life scenario, and in time becomes the dominant variant in the upper respiratory tract of the host.